Addex Therapeutics (ADXN)
NASDAQ:ADXN
Want to see ADXN full AI Analyst Report?
ADXN Stock Chart & Stats
$8.23
$0.23(2.80%)
At close: 4:00 PM EST
$8.23
$0.23(2.80%)
Day’s Range― - ―
52-Week Range$5.41 - $12.05
Previous CloseN/A
Volume26.36K
Average Volume (3M)16.10K
Market Cap
$6.90M
Enterprise Value$5.23M
Total Cash (Recent Filing)$1.64M
Total Debt (Recent Filing)$34.73K
Price to Earnings (P/E)―
Beta0.62
Next Earnings
May 25, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.10
Shares Outstanding1,822,121
10 Day Avg. Volume4,441
30 Day Avg. Volume16,099
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.20
Price to Sales (P/S)27.51
P/FCF Ratio-2.76
Enterprise Value/Market Cap0.76
Enterprise Value/Revenue60.90
Enterprise Value/Gross Profit-34.60
Enterprise Value/Ebitda-0.88
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-5.98
Revenue Forecast (FY)$1.79M
Bulls Say, Bears Say
Bulls Say
Pipeline & Allosteric Platform ProgressAddex’s core allosteric-modulation platform has advanced multiple programs to IND-enabling and strong preclinical readouts, de‑risking assets over the medium term. Sustained program progression improves partnership leverage and the probability of clinical-stage value realization independent of short-term markets.
Conservative Balance Sheet / Low LeverageVery low debt materially reduces bankruptcy and interest-rate risk, preserving optionality for licensing or bolt-on investments. While equity has been volatile, minimal leverage provides durable financial flexibility to pursue partnerships or structured non-dilutive deals versus highly leveraged peers.
Strategic Partnerships And Spin-out ValueThe Neurosterix spin-out funded early-stage development externally while leaving Addex with a meaningful equity stake, and partnership milestones (Indivior) offer sizable contingent upside. These structural moves lower funding needs and create potential non‑operational value capture over time.
Bears Say
Persistent Negative Cash GenerationOperating cash flow has been persistently negative, meaning Addex relies on external funding to sustain R&D. Even with improvement, continued cash consumption imposes durable financing risk, increases likelihood of dilution or asset monetization, and constrains independent program advancement.
Deep Operating Losses & Volatile ProfitabilityExtremely negative operating and net margins reflect a business still pre‑commercial and R&D intensive; absent major partner payments or product approvals, sustained losses will persist. Volatile profitability and prior equity swings indicate outcomes depend heavily on binary development events.
Limited Funding For Unpartnered Programs / Short RunwayReported cash runway only covers core operations into mid‑2026 but explicitly excludes advancing unpartnered programs. This structural funding gap forces prioritization, delays clinical progress for independent assets, and increases dependence on milestone payments or further financing.
Addex Therapeutics News
ADXN FAQ
What was Addex Therapeutics’s price range in the past 12 months?
Addex Therapeutics lowest stock price was $5.41 and its highest was $12.05 in the past 12 months.
What is Addex Therapeutics’s market cap?
Addex Therapeutics’s market cap is $6.90M.
When is Addex Therapeutics’s upcoming earnings report date?
Addex Therapeutics’s upcoming earnings report date is May 25, 2026 which is in 3 days.
How were Addex Therapeutics’s earnings last quarter?
Currently, no data Available
Is Addex Therapeutics overvalued?
According to Wall Street analysts Addex Therapeutics’s price is currently Overvalued.
Does Addex Therapeutics pay dividends?
Addex Therapeutics does not currently pay dividends.
What is Addex Therapeutics’s EPS estimate?
Addex Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Addex Therapeutics have?
Addex Therapeutics has 1,822,121 shares outstanding.
What happened to Addex Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Addex Therapeutics?
Currently, no hedge funds are holding shares in ADXN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Addex Therapeutics
Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The CharcotMarieTooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.
ADXN Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call highlighted significant progress in key programs and strategic collaborations, which are positive indicators for future growth. However, the need for additional funding for unpartnered programs and stable but limited income suggest challenges in financial sustainability.View all ADXN earnings summariesTechnical Analysis
Kiora Pharmaceuticals
―
Xenetic Biosciences
―
Nucana
―
Creative Medical Technology Holdings
―
HCW Biologics
―
Ownership Overview
―
Insiders
―
Mutual Funds
0.05% Other Institutional Investors
99.95% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---